Multispecific T-cell engagers in clinical trials for CLL and/or SLL
| NCT number . | Multispecific T-cell engager . | Target . | Title . | Status . | Intervention . |
|---|---|---|---|---|---|
| NCT04623541 | Epcoritamab | CD20 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome | Recruiting | Monotherapy or combination therapy: epcoritamab + venetoclax epcoritamab + lenalidomide epcoritamab + R-CHOP (ie, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine (Oncovin), and prednisone) |
| NCT06564038 | AZD0486 | CD19 | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | Not yet recruiting | AZD0486 + acalabrutinib, prednisone, rituximab |
| NCT04763083 | NVG-111 | ROR1 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies Conditions | Recruiting | Monotherapy |
| NCT00889408 | DT2219ARL | CD19 and CD22 | DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia or Lymphoma | Completed | Monotherapy |
| NCT02568553 | CD19 | Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma | Not yet recruiting | Blinatumumab + lenalidomide |
| NCT number . | Multispecific T-cell engager . | Target . | Title . | Status . | Intervention . |
|---|---|---|---|---|---|
| NCT04623541 | Epcoritamab | CD20 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome | Recruiting | Monotherapy or combination therapy: epcoritamab + venetoclax epcoritamab + lenalidomide epcoritamab + R-CHOP (ie, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine (Oncovin), and prednisone) |
| NCT06564038 | AZD0486 | CD19 | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | Not yet recruiting | AZD0486 + acalabrutinib, prednisone, rituximab |
| NCT04763083 | NVG-111 | ROR1 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies Conditions | Recruiting | Monotherapy |
| NCT00889408 | DT2219ARL | CD19 and CD22 | DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia or Lymphoma | Completed | Monotherapy |
| NCT02568553 | CD19 | Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma | Not yet recruiting | Blinatumumab + lenalidomide |